Monotherapy with pegylated interferon alpha-2a in hemodialyzed patients with chronic hepatitis C

Dialysis and Transplantation

Volumn 37, Issue 6, 2008, Pages 204-208

  Zoppoli, Gabriele ^a   Di Maio, Giovanni ^b   Artioli, Stefania ^c   Robaudo, Cristina ^b   Basso, Monica ^a   Torre, Francesco ^a   Cannella, Giuseppe ^b   Picciotto, Antonino ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONOTHERAPY; PANCYTOPENIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION;

EID: 54549087714     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20219     Document Type: Article

References (25)

1. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-909.
2. Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752-760.
3. Fabrizi F, de Vecchi AF, Como G, et al. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther. 2005;21:861-869.
4. Hu KQ, Lee SM, Hu SX, et al. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol. 2005;100:2010-2008.
5. Lopes EP, Gouveia EC, Albuquerque AC, et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35:298-302.
6. Yasuda K, Okuda K, Endo N, et al. Hypoamino-transferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995;109:1295-1300.
7. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis. 2004;24(Suppl 2):69-77.
8. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc. 2004;36:760-762.
9. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther. 2004;20:123-124; author reply 124.
10. Teta D, Luscher BL, Gonvers JJ, et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant. 2005;20:991-993.
11. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006;21:437-443.
12. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:575-580.
13. Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006;12:4191-4194.
14. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23-28.
15. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004;11:84-87.
16. Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18:1071-1081.
17. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 2006;26:305-310.
18. Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18:1573-1580.
19. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001;16:193-195.
20. Mousa DH, Abdalla AH, Al-Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831-1834.
21. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;19(Suppl 1):17-24.
22. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42:1109-1115.
23. Yagura M, Murai S, Kojima H, et al. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000;35:105-111.
24. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat. 2006;13:322-328.
25. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768-774.